AAAAAA

   
Results: 1-12 |
Results: 12

Authors: Teo, SK Evans, MG Brockman, MJ Ehrhart, J Morgan, JM Stirling, DI Thomas, SD
Citation: Sk. Teo et al., Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs, TOXICOL SCI, 59(1), 2001, pp. 160-168

Authors: Prehn, JL Landers, C Muller, GW Man, HW Stirling, DI Targan, SR
Citation: Jl. Prehn et al., Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues, J CLIN IMM, 21(5), 2001, pp. 357-364

Authors: Teo, SK Scheffler, MR Kook, KA Tracewell, WG Colburn, WA Stirling, DI Thomas, SD
Citation: Sk. Teo et al., Thalidomide dose proportionality assessment following single doses to healthy subjects, J CLIN PHAR, 41(6), 2001, pp. 662-667

Authors: Teo, SK Harden, JL Burke, AB Noormohamed, FH Youle, M Johnson, MA Peters, BS Stirling, DI Thomas, SD
Citation: Sk. Teo et al., Thalidomide is distributed into human semen after oral dosing, DRUG META D, 29(10), 2001, pp. 1355-1357

Authors: Davies, FE Raje, N Hideshima, T Lentzsch, S Young, G Tai, YT Lin, B Podar, K Gupta, D Chauhan, D Treon, SP Richardson, PG Schlossman, RL Morgan, GJ Muller, GW Stirling, DI Anderson, KC
Citation: Fe. Davies et al., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, BLOOD, 98(1), 2001, pp. 210-216

Authors: Teo, SK Scheffler, MR Kook, KA Tracewell, WG Colburn, WA Stirling, DI Thomas, SD
Citation: Sk. Teo et al., Effect of a high-fat meal on thalidomide pharmacokinetics and the relativebioavailability of oral formulations in healthy men and women, BIOPHARM DR, 21(1), 2000, pp. 33-40

Authors: Stirling, DI
Citation: Di. Stirling, Pharmacology of thalidomide, SEM HEMATOL, 37(1), 2000, pp. 5-14

Authors: Alexanian, R Anderson, KC Barlogie, B Stirling, DI Thomas, DA
Citation: R. Alexanian et al., Thalidomide in hematologic malignancies: Future directions, SEM HEMATOL, 37(1), 2000, pp. 35-39

Authors: Hideshima, T Chauhan, D Shima, Y Raje, N Davies, FE Tai, YT Treon, SP Lin, B Schlossman, RL Richardson, P Muller, G Stirling, DI Anderson, KC
Citation: T. Hideshima et al., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, BLOOD, 96(9), 2000, pp. 2943-2950

Authors: Muller, GW Chen, R Huang, SY Corral, LG Wong, LM Patterson, RT Chen, YX Kaplan, G Stirling, DI
Citation: Gw. Muller et al., Amino-substituted thalidoimide analogs: Potent inhibitors of TNF-alpha production, BIOORG MED, 9(11), 1999, pp. 1625-1630

Authors: Corral, LG Haslett, PAJ Muller, GW Chen, R Wong, LM Ocampo, CJ Patterson, RT Stirling, DI Kaplan, G
Citation: Lg. Corral et al., Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha, J IMMUNOL, 163(1), 1999, pp. 380-386

Authors: Stirling, DI
Citation: Di. Stirling, Thalidomide and its impact in dermatology, SEM CUT M S, 17(4), 1998, pp. 231-242
Risultati: 1-12 |